Entellus Medical

Investor Relations

We are a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of patients in the physician office setting or operating room who are suffering from chronic sinusitis. Our XprESS family of products is used by ear, nose and throat, or ENT, physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses.
Stock Information
ENTL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) - 0.01 (0.06%)
Data as of 11/17/17 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: ENTL.O.  Currently trading at $15.96 with a 52 week high of $20.34 and a 52 week low of $11.47.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Financial Reconciliations
Non-GAAP Financial Measure Reconciliations - Click Here
Recent NewsMore >>
11/14/17Entellus Medical to Participate in Upcoming Investor Conferences
11/13/17Anthem Inc. Issues Positive Coverage Decision for Balloon Sinus Dilation
11/01/17Entellus Medical Announces Third Quarter 2017 Financial Results
10/30/17Entellus Announces Long-Term Data Confirming the Durable Relief of Nasal Obstruction Symptoms with Latera® from Spirox®
Upcoming EventsMore >>
11/28/17 1:30 p.m. ET
Entellus Medical, Inc. at the 29th Annual Piper Jaffray Healthcare Conference
LocationNew York, NY
Entellus Medical, Inc. at the Guggenheim Healthcare Conference